| Title |
“Antivirals” in the Treatment of Adult T Cell Leukaemia– Lymphoma (ATLL)
|
|---|---|
| Published in |
Current Hematologic Malignancy Reports, October 2012
|
| DOI | 10.1007/s11899-012-0139-9 |
| Pubmed ID | |
| Authors |
Paul A. Fields, Graham P. Taylor |
| Abstract |
Adult T cell leukaemia / lymphoma (ATLL) is a mature (post thymic) T cell lymphoma caused by the human T-lymphotropic virus type 1 (HTLV-1) infection. Overall survival in the aggressive subtypes (Acute Leukaemia and Lymphomatous) remains poor in part due to chemotherapy resistance. To improve treatment outcome for de novo disease, better induction therapies are required and since the pathogenic agent is known it would seem sensible to target the virus. In a recent meta-analysis the use of zidovudine and interferon alpha (ZDV/IFN) has been associated with improved response rates and prolonged overall survival in leukemic subtypes of ATLL (both acute and Chronic) confirmed in a multivariate analysis. In a more recent UK study the overall response rate for patients with aggressive ATLL treated with chemotherapy alone was 49 % compared to 81 % with combined first line therapy (chemotherapy with concurrent or sequential ZDV/IFN). Combined first line therapy prolonged median OS in acute (p = 0.0081) and lymphomatous ATLL (p = 0.001).These data support the use of low dose ZDV/IFN with chemotherapy as first line treatment for patients with newly diagnosed aggressive ATLL. Although the mechanisms of action are incompletely understood, some possible explanations for their efficacy will be discussed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 28 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 30% |
| Other | 5 | 17% |
| Student > Bachelor | 3 | 10% |
| Student > Master | 3 | 10% |
| Student > Ph. D. Student | 2 | 7% |
| Other | 6 | 20% |
| Unknown | 2 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 50% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Agricultural and Biological Sciences | 3 | 10% |
| Unspecified | 2 | 7% |
| Nursing and Health Professions | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 3 | 10% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2012.
All research outputs
#18,319,742
of 22,684,168 outputs
Outputs from Current Hematologic Malignancy Reports
#323
of 427 outputs
Outputs of similar age
#140,063
of 183,365 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#4
of 5 outputs
Altmetric has tracked 22,684,168 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 427 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 183,365 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.